01 Increasing Adoption of Evidence-Based Digital Therapeutics for Chronic and Behavioral Health Conditions Evidence-based digital interventions are gaining broader adoption for chronic disease management, mental health, behavioral health, rehabilitation, and preventive care. These solutions can extend therapeutic support beyond traditional clinical settings while enabling continuous patient engagement and personalized interventions. As healthcare providers and payers increasingly evaluate clinically validated software as part of care pathways, the Digital Therapeutics (DTx) Market is moving from standalone digital applications toward more clinically integrated treatment models. In March 2026, IEEE highlighted the continued growth of digital prescription therapeutics and medical-grade mobile health applications, alongside increasing demand for stronger clinical, technical, and ethical safeguards.
02 Growing Integration of Artificial Intelligence and Connected Technologies in Digital Therapeutics Artificial intelligence, wearable devices, remote monitoring, and connected health technologies are increasingly being integrated into digital therapeutic platforms to support personalized and adaptive interventions. These technologies can analyze patient-generated data, identify changes in symptoms or behavior, and adjust therapeutic support according to individual needs. This shift is expanding the capabilities of digital therapeutics and strengthening their role in continuous and personalized care delivery. In July 2026, industry research identified AI-powered therapeutics, wearable-integrated solutions, and personalized digital care as major factors accelerating adoption across digital therapeutic applications.
01 Rising Chronic Disease Burden and Demand for Remote Care Support Digital Therapeutics Adoption The growing prevalence of chronic and behavioral health conditions is increasing demand for scalable treatment solutions that can support patients outside hospitals and clinics. Digital therapeutics can provide structured interventions, behavioral support, monitoring, and treatment guidance through software platforms, helping extend care to patients who face access or capacity limitations. The continued shift toward remote and patient-centered healthcare is therefore supporting adoption across multiple therapeutic areas.
01 Limited and Fragmented Reimbursement Coverage Can Restrict Digital Therapeutics Adoption Digital therapeutics continue to face reimbursement barriers because payment structures, coverage policies, and evaluation requirements differ across healthcare systems and insurers. Regulatory authorization alone does not guarantee reimbursement, requiring developers to demonstrate clinical and economic value before payers commit to coverage. These fragmented reimbursement pathways can delay commercialization, increase market-entry costs, and limit patient access to digitally delivered treatments.
01 Expansion of AI-Enabled Personalized Therapies Creates New Growth Opportunities Artificial intelligence is creating opportunities to make digital therapeutics more adaptive by tailoring interventions according to patient behavior, symptoms, treatment responses, and continuously collected health data. These capabilities create opportunities for digital therapeutics to expand into chronic disease management, preventive care, mental health, and other long-term treatment applications.
01 Demonstrating Long-Term Clinical Effectiveness and Patient Engagement Remains a Challenge Digital therapeutics must demonstrate sustained clinical outcomes while maintaining patient engagement, usability, adherence, data security, and integration with healthcare workflows. High dropout rates or inconsistent usage can reduce the effectiveness of interventions and weaken real-world evidence. Developers must therefore establish robust clinical validation and demonstrate measurable long-term value to healthcare providers, payers, and patients.
June 2026 Click Therapeutics expanded its prescription digital therapeutics portfolio with continued commercialization and development of software-based treatments for mental health and chronic conditions. The company focused on integrating clinically validated digital interventions into healthcare delivery.
March 2026 Better Therapeutics expanded its digital therapeutic solutions focused on cardiometabolic conditions through technology-driven behavioral interventions. The company continued advancing software-based approaches designed to support chronic disease management.
January 2026 Akili expanded its digital medicine platform with new applications of its video game-based therapeutic technology. The company continued developing prescription digital therapeutics designed to improve cognitive function and neurological health outcomes.
October 2025 Pear Therapeutics’ digital therapeutic technology assets were expanded through continued industry adoption and integration by healthcare technology providers. The solutions support software-based interventions for behavioral health and chronic disease management.